Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

CLARIFICATION ANNOUNCEMENT

Reference is made to the annual general meeting (the "**AGM**") circular (the "**AGM Circular**") of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**") dated April 23, 2026. Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the AGM Circular.

The Company noted an inadvertent clerical error on page 15 of the AGM Circular in respect of the special resolution relating to "6. Proposed Application for Comprehensive Credit Facilities and Provision of Guarantee for the Company and Subsidiaries" as contained in the Letter from the Board in the AGM Circular. The Company would like to clarify that relevant paragraphs of the aforesaid special resolution as stated in the AGM Circular should be read as follow (with the correction underlined):

"In order to meet the needs of the Company's production and operation, the Company and its subsidiaries intend to apply for a consolidated credit line of not more than RMB1.5 billion from the banks, which will be used to apply for various projects including but not limited to working capital loans, project capital loans, letters of credit, bank acceptances, packaged loans, letters of guarantee, factoring, and other lending and financing businesses. The specific amount of credit facilities will be determined based on the working capital of the Company and the actual credit limit approved by the bank. The aforesaid credit line may be applied for within one year from the date on which this proposal is considered and approved at the AGM.

At the same time, in order to meet the needs of other wholly-owned subsidiaries of the Company to apply for credit from banks and handle financing, the Company agreed to provide joint and several liability guarantee for the loans incurred by other wholly-owned subsidiaries of the Company within the aforesaid annual credit limit (with the cumulative total amount not exceeding RMB1.5 billion), and the specific content of such guarantee shall be subject to the formally signed guarantee documents."

Save for the above, all other information stated in the AGM Circular remain unchanged. This clarification announcement is supplemental to and should be read in conjunction with the AGM Circular.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, May 7, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang, Ms. Zhang Leidi and Dr. Liu Hongkang as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.